Nebenwirkungen · Opuviz
Opuviz 40 mg/mL solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 37
HOS-151219 · Präparat HOS-100479
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials in patients with AMD, DME, RVO, myopic CNV and ROP. Across indications no notable difference between the groups treated with aflibercept and the respective comparator groups were observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:20:00Z · SHA-256 8550c96e188926417c9c3c21b2e5b3429c3532352a0c21874ae323a63dec6ea7 · Passage 50fb2067f4f693cf32c7e6ec619bd14cc9f4103b8a266dbb3be00df0b40610b2 · Zeichen 4643–5194 im Abschnitt